awmsg logo



octreotide (Sandostatin® LAR®)


Reference No. 3732

Publication date:
25/09/2018


Appraisal information

octreotide (Sandostatin® LAR®) 10 mg powder and solvent for suspension for injection
octreotide (Sandostatin® LAR®) 20 mg powder and solvent for suspension for injection
octreotide (Sandostatin® LAR®) 30 mg powder and solvent for suspension for injection


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 11/07/2018
AWMSG meeting date: 12/09/2018
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1518
Ratification by Welsh Government: 20/09/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Octreotide (Sandostatin® LAR®) is recommended as an option for use within NHS Wales for the treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download